Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Alzheimer's Disease
Dementia
Dementia with Lewy Bodies
Frontotemporal Dementia
Vascular Dementia
Mild Cognitive Impairment
View all Diseases
Topics
Diagnostics
Biology
Communication
Treatment
Care Practice
Prevention
View all Topics
Conferences
AD/PD 2023
ARUK 2023
CTAD 2022
AAIC 2022
EAN 2022
ESOC 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Dementia
3:14
The effect of APOE4 on neurovascular coupling
Silvia Anderle
• 24 Apr 2023
4:01
Use of AD blood-based biomarkers for trial enrolment
Philip Tipton
• 27 Apr 2023
1:19
Expanding research into biomarkers for RPD differentiation
Philip Tipton
• 27 Apr 2023
5:36
Characterizing protein accumulation in primary vulnerable neurons in Alzheimer’s disease
Alessia Caramello
• 25 Apr 2023
2:34
Investigating the link between APOE4, vascular function, & Alzheimer’s disease onset
Silvia Anderle
• 24 Apr 2023
4:37
Epigenome-wide association study of psychosis in Alzheimer’s disease
Morteza Kouhsar
• 24 Mar 2023
2:21
How feasible is an Alzheimer’s disease blood test in the UK?
Amanda Heslegrave
• 10 Mar 2023
3:28
Diagnostic biomarkers on the horizon in Alzheimer’s disease
Amanda Heslegrave
• 10 Mar 2023
1:21
TREM2 as a target for disease modification in Alzheimer’s disease
Elina Svensson
• 6 Apr 2023
2:26
Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials
Stephen Salloway
• 19 Apr 2023
1:25
Hearing loss and dementia
M. Florencia Iulita
• 28 Mar 2023
3:48
The power of composite tests to track Alzheimer’s disease progression
Suzanne Hendrix
• 21 Mar 2023
3:25
Trends in the use of surrogate biomarkers during clinical trials
Suzanne Hendrix
• 21 Mar 2023
2:10
Streamlining dementia diagnosis with digital biomarkers
M. Florencia Iulita
• 28 Mar 2023
1:56
Best outcome measures for Alzheimer’s disease follow-up in the clinic
Giovanni Frisoni
• 30 Mar 2023
2:48
TRAILBLAZER-ALZ 4: direct comparison of donanemab and aducanumab
Stephen Salloway
• 19 Apr 2023
1
2
3
4
5
…
51
Next